Dr. Reddy’s to acquire Slayback’s eyedrop rights
[ad_1] Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph […]
Continue Reading